BRIANNE SHERGILL Portfolio
Invests via Exome Asset Management LLC | Managed by BRIANNE SHERGILL
Invests via Exome Asset Management LLC
Managed by BRIANNE SHERGILL
Automatically Tracked
BRIANNE SHERGILL Profile
Operating executive and investor focused on growth-stage technology and consumer companies, with experience scaling product, marketing and commercial teams across digital platforms. BRIANNE SHERGILL brings a cross-functional background in product-led growth, go-to-market strategy and M&A integration, and is often active in advisory and board roles for startups and venture firms. Market relevance: expertise in SaaS and direct-to-consumer monetization and customer acquisition economics.
Operating executive and investor focused on growth-stage technology and consumer companies, with experience scaling product, marketing and commercial teams across digital platforms. BRIANNE SHERGILL brings a cross-functional background in product-led growth, go-to-market strategy and M&A integration, and is often active in advisory and board roles for startups and venture firms. Market relevance: expertise in SaaS and direct-to-consumer monetization and customer acquisition economics.
Investment Philosophy & Strategy
Focuses on growth-stage technology and consumer companies, prioritizing product-led SaaS and direct-to-consumer models where unit economics improve with scalable customer acquisition. Capital allocation favors follow-on rounds and strategic seed-to-Series B investments paired with active advisory or board participation to drive GTM, product-market fit and M&A readiness. Emphasizes metric-driven decisions, short-to-medium horizon value creation, disciplined downside protection and operational hands-on execution as the primary edge.
Focuses on growth-stage technology and consumer companies, prioritizing product-led SaaS and direct-to-consumer models where unit economics improve with scalable customer acquisition. Capital allocation favors follow-on rounds and strategic seed-to-Series B investments paired with active advisory or board participation to drive GTM, product-market fit and M&A readiness. Emphasizes metric-driven decisions, short-to-medium horizon value creation, disciplined downside protection and operational hands-on execution as the primary edge.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
96.87%
Gain +1.4%
Monthly
2.33%
Yearly
31.82%
Drawdown
23.38%
$172.05M
Equity
Holdings
$172.05M
Investment
$110.07M
$123.5M
Profit +$3.21M
Realized
$61.52M
Unrealized
$61.98M
Dividends
$455,580.22
Goals
Avg. 0% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
1.4%
Profit
$3.21M
Win %
74%
This Week
Compared To Last Week
Gain
1.9%
Profit
$3.21M
Win %
74%
This Month
Compared to last month
Gain
-1.69%
Profit
-$2.96M
Win %
74%
This Year
Compared to last year
Gain
-30.53%
Profit
-$61.2M
Win %
82%
ALMS Alumis Inc.
+15.55%
+$907,322 
ELVN Enliven Therapeutics, Inc.
+14.3%
+$1.27M 
ZBIO Zenas BioPharma, Inc.
+11.49%
+$164,689.2 
AVTX Avalo Therapeutics Inc.
+7.97%
+$173,681.69 
PRAX Praxis Precision Medicines Inc.
+7.5%
+$845,722.95 
GLUE Monte Rosa Therapeutics, Inc.
+6.64%
+$203,714.34 
MLTX MoonLake Immunotherapeutics
+5.3%
+$202,453.44 
CRBP Corbus Pharmaceuticals Holdings, Inc.
+5.27%
+$95,995.76 
VSTM Verastem Inc.
+4.06%
+$101,872 
RLAY Relay Therapeutics Inc.
+4%
+$158,632.14 
LPCN Lipocine Inc.
+2.73%
+$3,651.66 
AGIO Agios Pharmaceuticals Inc.
+2.58%
+$92,544.4 
GKOS Glaukos Corporation
+2.05%
+$53,228.7 
VERA Vera Therapeutics Inc.
+1.81%
+$70,144.51 
COGT Cogent Biosciences, Inc.
+1.47%
+$133,695.28 
NBP NovaBridge Biosciences American Depositary Shares
+1.36%
+$11,539.2 
CYTK Cytokinetics, Incorporated
+1.27%
+$91,271.84 
INSM Insmed Inc.
+1.17%
+$30,115.63 
CTMX CytomX Therapeutics Inc.
+1.01%
+$15,644.04 
RYTM Rhythm Pharmaceuticals Inc.
+0.82%
+$29,218.32 
UNH UnitedHealth Group Incorporated
+0.73%
+$38,200.14 
GH Guardant Health Inc.
+0.55%
+$59,570.75 
PEN Penumbra Inc.
+0.12%
+$2,456.87 
UTHR United Therapeutics Corporation
+0.1%
+$3,949.68 
ANTM Anthem Inc
0%
$0 
APLS Apellis Pharmaceuticals Inc.
0%
$0 
ARWR
0%
$0 
SLNO Soleno Therapeutics, Inc.
0%
$0 
NXTC NextCure, Inc.
-6.95%
-$17,902.5 
PALI Palisade Bio Inc.
-3.93%
-$42,000 
ESTA Establishment Labs Holdings Inc.
-3.49%
-$38,907 
NTRA NATERA INC (Common Stock) – ticker 45E
-3.27%
-$133,533.87 
LLY Eli Lilly and Company
-2.41%
-$195,985.05 
CBIO Crescent Biopharma, Inc.
-2.29%
-$64,340.22 
ALKS Alkermes plc
-1.43%
-$53,825.92 
BBIO BridgeBio Pharma, Inc.
-1.11%
-$50,619 
IONS Ionis Pharmaceuticals, Inc.
-0.73%
-$59,434.56 
TXG 10x Genomics Inc.
-0.72%
-$32,380.59 
ABUS Arbutus Biopharma Corporation
-0.7%
-$2,264.52 
LQDA Liquidia Corporation
-0.56%
-$18,318.4 
BSX Boston Scientific Corporation
-0.55%
-$12,570.22 
ISRG Intuitive Surgical, Inc.
-0.45%
-$11,698.67 
ADAG Adagene Inc.
-0.28%
-$7,368.45 
MAZE Maze Therapeutics Inc.
-0.17%
-$3,540.49 
FDMT 4D Molecular Therapeutics, Inc.
-0.06%
-$652.82 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 458 | Longs Won 211/458 46% | Profit Factor 4.56 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.08M |
| Average Win $746,966.96 | Best Trade (Dec 31) $11.09M | Sharpe Ratio -22.19 |
| Average Loss -$139,875.52 | Worst Trade (Sep 30) -$2.87M | Z-Score -5.66 (100%) |
| Commissions $0 | Avg. Trade Length 6m 2w 3d | Expectancy $269,655.53 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.02% |
| Consecutive Losing Trades | 1,230 | 1,107 | 984 | 861 | 738 | 615 | 492 | 369 | 246 | 123 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
